Evidence map›Paper›PMID 30482770›Full record

ReviewBlood advances2018

Clinical consequences of clonal hematopoiesis of indeterminate potential.

David P Steensma

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04689750 (Impact of Donor Clonal Haematopoiesis of Indeterminate Potential), which is not on this map. Cited by 118 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 4 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04689750 recruitingnot on this mapstarted 2021, after this paper: background citation

Impact of Donor Clonal Haematopoiesis of Indeterminate Potential (CHIP) on Recipient Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (Allo-HSCT)

TypeobservationalSponsorThe University of Hong KongRan2021 to 2026Enrolled850ConditionsClonal HematopoiesisArmsNext generation sequencing
3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 4 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. The Landscape of Genomic and Socioeconomic Variables in Patients with Colorectal Cancer Based on Genetic Ancestry.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  8. Ki-67 Expression in megakaryocytes: A new prognostic marker in Myelodysplastic Syndromes.Virchows Archiv : an international journal of pathology · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Review
  15. Review
  16. Clonal Hematopoiesis and Thrombosis.American journal of hematology · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

David P SteensmaDana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Harvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clonally restricted hematopoiesis is a common aging-associated biological state that predisposes to subsequent development of a hematological malignancy or cardiovascular death. Clonal expansion driven by leukemia-associated somatic mutations, such as

Indexed as

Cardiovascular DiseasesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AHematologic DiseasesHematopoiesisHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansRepressor ProteinsASXL1 protein, humanDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanRepressor Proteins

Identifiers

PMID30482770
PMCPMC6258914
OpenAlexW4231048062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.